ARCHIVES

Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 1 | January 27, 2012

Download PDF Visit The Full Archive

Related Articles

Herberman Leaving NCI To Head New Pittsburgh Institute

July 12, 1985

In Brief: Interim Dean Henney Looking for Cancer Center Director; Shingleton Gets James Ewing Award

June 10, 1988

Tafinlar Subgroup Data Shows Median OS of 20 Months

October 31, 2014

CTEP Publishes Final Version of Plan for Assigning Intellectual Property Rights On Correlative Research

April 8, 2011

Senate Bill Would Prohibit Political Appointments To Advisory Groups

January 9, 1976

AMA Supports Right To Silicone Implants, Kessler Takes Issues

December 3, 1993